Interferon Lambda for Immediate Antiviral Therapy at Diagnosis in COVID-19 (ILIAD)

• ClinicalTrials.gov Identifier: NCT04354259
• Recruitment Status: Recruiting
• First Posted: April 21, 2020
• Last Update Posted: January 19, 2022
• Sponsor: University Health Network, Toronto
• Collaborator: Michael Garron Hospital
• Information provided by (Responsible Party): University Health Network, Toronto

Study Description

Brief Summary:

Interferon lambda is one of the main arms of the innate antiviral immune response and is critical for controlling respiratory viral infections in mice. Interferon lambda has a better side effect profile than other interferons because of the limited tissue distribution of its receptor. Peginterferon lambda is a long-acting form that has been studied extensively in human trials in viral hepatitis, confirming its safety. We propose to evaluate peginterferon-lambda in ambulatory and hospitalized patients with mild to moderate COVID-19.

Condition or disease	Intervention/treatment	Phase
Sars-CoV2; Covid-19	Drug: Peginterferon Lambda-1A; Other: placebo	Phase 2

Detailed Description:

The study uses an adaptive design with initial enrolment in the Ambulatory cohort (Cohort A) followed by a safety assessment before initiation of enrolment in the Hospitalized cohort (Cohort B).

Ambulatory patients (Cohort A) with confirmed COVID-19 deemed well enough for home isolation will be randomized to receive a single subcutaneous injection of Peginterferon lambda 180µg or saline placebo prior to discharge. Patients will be followed remotely with visits for a repeat swab at Day 3 and 7 with the primary endpoint being the proportion positive for SARS-CoV-2 on Day 7.

Safety data will be reviewed by the Data Safety and Monitoring Committee after 50% of the Ambulatory cohort (n=60) has been enrolled. If the committee approves study continuation, enrolment will continue in the Ambulatory cohort (Cohort A) and will begin in the Hospitalized cohort (Cohort B).

Hospitalized patients (Cohort B) with moderate but not severe COVID-19 will be enrolled and randomized to Peginterferon lambda 180µg or saline placebo on Day 0 and 5. The primary endpoint will be clinical outcomes on the WHO ordinal scale. In addition to the primary endpoint on which the study is powered, numerous secondary endpoints will be evaluated. Samples will also be collected for ancillary studies to better understand predictors of disease severity and response to treatment.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 240 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: Interferon Lambda for Immediate Antiviral Therapy at Diagnosis (ILIAD): A Phase II Randomized, Double-blind, Placebo-controlled, Multicenter Trial to Evaluate the Effect of Peginterferon Lambda for the Treatment of COVID-19
• Actual Study Start Date: May 13, 2020
• Estimated Primary Completion Date: December 15, 2022
• Estimated Study Completion Date: January 15, 2023

Arms and Interventions

Arm	Intervention/treatment
Experimental: Ambulatory Cohort - Treatment; to receive a single dose of peginterferon lambda 180µg SC at baseline (day 0).	Drug: Peginterferon Lambda-1A; Peginterferon lambda is a covalent conjugate of human recombinant non-pegylated IFN lambda (IFN L) and a 20-kDa linear PEG chain. Peginterferon lambda Injection is a sterile, nonpyrogenic, ready-to-use solution (0.4 mg/mL) that is clear to opalescent, colorless to pale yellow, and essentially free of particles. Lambda Injection is provided in a 1-mL long Type I glass syringe (0.18 mg/syringe) with a staked 29-gauge, 1/2- inch, thin-walled needle. The syringe has a rigid needle shield and is stoppered with a plunger stopper. Syringes are prefilled with a solution of Peginterferon lambda Injection, mannitol, L-histidine, polysorbate 80, hydrochloric acid, and water for injection; they are intended for a single use at adjustable doses. The syringe is marked with dose indicator lines, which are used as a reference point for administering the correct dose.
Placebo Comparator: Ambulatory Cohort - placebo; Patients in the arm will be given a single injection of 0.9% sodium chloride (normal saline) solution at baseline (day 0). A plastic 1 mL syringe will be prefilled by the study pharmacy. Each syringe will contain 0.5 mL (0.45 mL to match the volume of the Interferon plus 0.05 mL overfill) to allow for needle priming by the unblinded study nurse.	Other: placebo; injection of 0.9% sodium chloride (normal saline) solution. A plastic 1 mL syringe will be prefilled by the study pharmacy. Each syringe will contain 0.5 mL (0.45 mL to match the volume of the Interferon plus 0.05 mL overfill) to allow for needle priming by the unblinded study nurse.
Experimental: Hospitalized Cohort - Treatment; To receive a dose of peginterferon lambda 180µg SC at baseline and a second dose on day 5.	Drug: Peginterferon Lambda-1A; Peginterferon lambda is a covalent conjugate of human recombinant non-pegylated IFN lambda (IFN L) and a 20-kDa linear PEG chain. Peginterferon lambda Injection is a sterile, nonpyrogenic, ready-to-use solution (0.4 mg/mL) that is clear to opalescent, colorless to pale yellow, and essentially free of particles. Lambda Injection is provided in a 1-mL long Type I glass syringe (0.18 mg/syringe) with a staked 29-gauge, 1/2- inch, thin-walled needle. The syringe has a rigid needle shield and is stoppered with a plunger stopper. Syringes are prefilled with a solution of Peginterferon lambda Injection, mannitol, L-histidine, polysorbate 80, hydrochloric acid, and water for injection; they are intended for a single use at adjustable doses. The syringe is marked with dose indicator lines, which are used as a reference point for administering the correct dose.
Placebo Comparator: Hospitalized Cohort - placebo; Patients in the arm will be given an injection of 0.9% sodium chloride (normal saline) solution at baseline (day 0). A plastic 1 mL syringe will be prefilled by the study pharmacy. Each syringe will contain 0.5 mL (0.45 mL to match the volume of the Interferon plus 0.05 mL overfill) to allow for needle priming by the unblinded study nurse. Patients will be administered a second dose of placebo on day 5.	Other: placebo; injection of 0.9% sodium chloride (normal saline) solution. A plastic 1 mL syringe will be prefilled by the study pharmacy. Each syringe will contain 0.5 mL (0.45 mL to match the volume of the Interferon plus 0.05 mL overfill) to allow for needle priming by the unblinded study nurse.

Outcome Measures

Primary Outcome Measures :

1. Cohort A (Ambulatory) - Proportion swab negative at day 7 (Primary efficacy endpoint) [ Time Frame: At day 7 ]
   The proportion of participants with negative SARS-CoV-2 RNA on nasopharyngeal swab.
2. Cohort A (Ambulatory) - Treatment-emergent and treatment related serious adverse events (Primary Safety Endpoint) [ Time Frame: Day 0 to Day 28 ]
   The rate of treatment-emergent and treatment-related serious adverse events (SAEs)
3. Cohort B (Hospitalized) - Ordinal Scale (Primary Efficacy Endpoint) [ Time Frame: At Day 14 ]
   Clinical status on an ordinal scale at Day 14
4. Cohort B (Hospitalized) - treatment-emergent and treatment-related serious adverse events (Primary Safety Endpoint) [ Time Frame: Day 0 to Day 28 ]
   The rate of treatment-emergent and treatment-related serious adverse events (SAEs)

Secondary Outcome Measures :

1. Cohort A (Ambulatory) - Symptom Resolution (Clinical Outcome #1) [ Time Frame: Day 0 to Day 14 ]
   Time to resolution of symptoms (fever, cough, diarrhea)
2. Cohort A (Ambulatory) - Symptom severity scores (Clinical Outcome #2) [ Time Frame: Day 0 to Day 7 ]
   Change in relative categorical symptom scores (respiratory, gastrointestinal, fever) - none, mild, moderate, severe and no change, worse, better
3. Cohort A (Ambulatory) - Hospitalization (Clinical Outcome #3) [ Time Frame: Day 0 to Day 14 ]
   Proportion with need for hospital admission
4. Cohort A (Ambulatory) - Adverse and serious adverse events (Clinical Outcome #4) [ Time Frame: Day 0 to Day 14 ]
   Adverse events and serious adverse events
5. Cohort A (Ambulatory) - Swab negative at day 3 (Virologic/Immunological Outcome #1) [ Time Frame: At Day 3 ]
   Proportion negative for SARS-CoV-2 RNA by nasopharyngeal swab
6. Cohort A (Ambulatory) - Time RNA negativity (Virologic/Immunological Outcome #2) [ Time Frame: Day 0 to Day 14 ]
   Time to SARS-CoV-2 RNA negativity on mid-turbinate nasal swab or saliva
7. Cohort A (Ambulatory) - Proportion viremic (Virologic/Immunological Outcome #3) [ Time Frame: Day 0 and Day 7 ]
   Proportion with SARS-CoV-2 RNA in blood.
8. Cohort A (Ambulatory) - Proportion with antibodies (Virologic/Immunological Outcome #4) [ Time Frame: Day 0 and Day 7 ]
   Proportion with SARS-CoV-2 antibodies blood
9. Cohort A (Ambulatory) - Correlation with interferon lambda 4 genotype (Virologic/Immunological Outcome #5) [ Time Frame: Through day 7 ]
   Correlation of virologic response with interferon lambda 4 (IFNL4) genotype
10. Cohort A (Ambulatory) - Symptoms in household contacts (Transmission Outcome #1) [ Time Frame: Day 0 to Day 14 ]
    Proportion with symptom development in household contacts (categorical symptom type yes/no)
11. Cohort A (Ambulatory) - COVID-19 in household contacts (Transmission Outcome #2) [ Time Frame: At Day 30 ]
    Proportion with confirmed diagnosis of COVID-19 in household contacts
12. Cohort B (Hospitalized) - Ordinal scale (Clinical Outcome #1) [ Time Frame: At Days 7, 21 and 28 ]
    Clinical status on the ordinal scale
13. Cohort B (Hospitalized) - ICU admission (Clinical Outcome #2) [ Time Frame: Day 0 to day 28 ]
    Proportion with ICU admission during hospitalization
14. Cohort B (Hospitalized) - Need for intubation (Clinical Outcome #3) [ Time Frame: Day 0 to Day 14 and to Day 28 ]
    Proportion with need for intubation
15. Cohort B (Hospitalized) - Length of hospital stay (Clinical Outcome #4) [ Time Frame: Day 0 to Day 14 ]
    Length of hospital stay (days)
16. Cohort B (Hospitalized) - Change in respiratory symptom score (Clinical Outcome #5) [ Time Frame: Day 0 to 7, Day 0 to 14, and Day 0 to 28 ]
    Change in respiratory symptom score (score 0 to 7 with higher scores indicating more severe disease)
17. Cohort B (Hospitalized) - All-cause mortality (Clinical Outcome #6) [ Time Frame: At day 28 and day 90 ]
    All-cause mortality
18. Cohort B (Hospitalized) - Readmission to hospital (Clinical Outcome #7) [ Time Frame: From Day 0 -28 and from Day 0 - 90 ]
    Proportion with readmission to hospital
19. Cohort B (Hospitalized) - COVID-19-related mortality (Clinical Outcome #8) [ Time Frame: At day 28 ]
    COVID-19-related mortality
20. Cohort B (Hospitalized) - Adverse (AEs) and Serious Adverse Events (SAEs) (Clinical Outcome #9) [ Time Frame: Day 0 to day 28 ]
    Adverse (AEs) and Serious Adverse Events (SAEs)
21. Cohort B (Hospitalized) - Dose reduction or dose omission (Clinical Outcome #10) [ Time Frame: Day 5 to day 9 ]
    Frequency of dose reduction or dose omission for the second dose of peginterferon lambda
22. Cohort B (Hospitalized) - Time to viral negativity (Virologic/Immunological Outcome #1) [ Time Frame: Day 0 - Day 28 ]
    Time to SARS-CoV-2 RNA negativity.
23. Cohort B (Hospitalized) - Proportion negative swab. (Virologic/Immunological Outcome #2) [ Time Frame: Days 0-7, 10, 12, 14, 18, 21, 25 and 28 ]
    Proportion negative for SARS-CoV-2 RNA by mid-turbinate swab
24. Cohort B (Hospitalized) - Quantitative viral load by nasal swab (Virologic/Immunological Outcome #3) [ Time Frame: Day 0 - Day 28 ]
    Change in quantitative SARS-CoV-2 RNA by mid-turbinate swab over time
25. Cohort B (Hospitalized) - Correlation with interferon lambda 4 (IFNL4) genotype (Virologic/Immunological Outcome #4) [ Time Frame: Through Day 14 ]
    Correlation of virologic response with interferon lambda 4 (IFNL4) genotype
26. Cohort B (Hospitalized) - Safety Markers (Virologic/Immunological Outcome #5) [ Time Frame: From Day 0 - Day 7 and to Day 14, 21, and 28 ]
    Change in hemoglobin over time.
27. Cohort B (Hospitalized) - Safety Markers (Virologic/Immunological Outcome #6) [ Time Frame: From Day 0 - Day 7 and to Day 14, 21, and 28 ]
    Change in white blood cell count over time.
28. Cohort B (Hospitalized) - Safety Markers (Virologic/Immunological Outcome #7) [ Time Frame: From Day 0 - Day 7 and to Day 14, 21, and 28 ]
    Change in lymphocyte count over time.
29. Cohort B (Hospitalized) - Safety Markers (Virologic/Immunological Outcome #8) [ Time Frame: From Day 0 - Day 7 and to Day 14, 21, and 28 ]
    Change in platelet count over time.
30. Cohort B (Hospitalized) - Safety Markers (Virologic/Immunological Outcome #9) [ Time Frame: From Day 0 - Day 7 and to Day 14, 21, and 28 ]
    Change in ALT over time.
31. Cohort B (Hospitalized) - Safety Markers (Virologic/Immunological Outcome #10) [ Time Frame: From Day 0 - Day 7 and to Day 14, 21, and 28 ]
    Change in AST over time.
32. Cohort B (Hospitalized) - Safety Markers (Virologic/Immunological Outcome #11) [ Time Frame: From Day 0 - Day 7 and to Day 14, 21, and 28 ]
    Change in ALP over time.
33. Cohort B (Hospitalized) - Safety Markers (Virologic/Immunological Outcome #12) [ Time Frame: From Day 0 - Day 7 and to Day 14, 21, and 28 ]
    Change in bilirubin over time.
34. Cohort B (Hospitalized) - Safety Markers (Virologic/Immunological Outcome #13) [ Time Frame: From Day 0 - Day 7 and to Day 14, 21, and 28 ]
    Change in albumin over time.
35. Cohort B (Hospitalized) - Inflammatory Markers (Virologic/Immunological Outcome #14) [ Time Frame: From Day 0 - Day 7 and to Day 14, 21, and 28 ]
    Change in ferritin over time.
36. Cohort B (Hospitalized) - Inflammatory Markers (Virologic/Immunological Outcome #15) [ Time Frame: From Day 0 - Day 7 and to Day 14, 21, and 28 ]
    Change in lactate dehydrogenase over time.
37. Cohort B (Hospitalized) - Inflammatory Markers (Virologic/Immunological Outcome #16) [ Time Frame: From Day 0 - Day 7 and to Day 14, 21, and 28 ]
    Change in c-reactive protein over time
38. Cohort B (Hospitalized) - Inflammatory Markers (Virologic/Immunological Outcome #17) [ Time Frame: From Day 0 - Day 7 and to Day 14, 21, and 28 ]
    Change in D-dimers over time.
39. Cohort B (Hospitalized) - Inflammatory Markers (Virologic/Immunological Outcome #18) [ Time Frame: From Day 0 - Day 7 and to Day 14, 21, and 28 ]
    Change in creatine kinase over time.
40. Cohort B (Hospitalized) - Inflammatory Markers (Virologic/Immunological Outcome #19) [ Time Frame: From Day 0 - Day 7 and to Day 14, 21, and 28 ]
    Change in troponin over time.
41. Cohort B (Hospitalized) - Proportion with Antibody (Virologic/Immunological) Outcome #20) [ Time Frame: At Day 7, 14, 21, and 28 ]
    Proportion with SARS-CoV-2 Antibody.
42. Cohort B (Hospitalized) - Proportion with viremia (Virologic/Immunological Outcome #21) [ Time Frame: Day 0, Day 7, 14, 21, and 28 ]
    Proportion with SARS-CoV-2 RNA in blood

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Cohort A - Ambulatory

Inclusion Criteria

1. Adult patients between the ages of 18 and 75 years.
2. Confirmed COVID-19 infection by PCR within 7 days of symptom onset (fever, respiratory symptoms, sore throat).
3. Discharged to home isolation.
4. Willing and able to sign informed consent.
5. Willing and able to follow-up by daily phone or videoconference.

6. Female patients of childbearing potential and male patients with partners of childbearing potential must agree to use adequate methods of contraception during the study and through 90 days after the last dose of study medication. Female patients of childbearing potential are all those except patients who are surgically sterile, who have medically documented ovarian failure, or who are at least 1 year postmenopausal. Adequate methods of contraception are:

   a. For female patients i. Hormonal contraceptives including progestogen injection (eg, Depo-Provera®), combined oral contraceptive pill or vaginal ring for ≥ 3 months before screening AND a barrier method (use of condom [male partner] or diaphragm with spermicide or cervical cap with spermicide) from screening, or ii. Intrauterine device (IUD) or intrauterine system (IUS) in place ≥ 3 months before screening AND a barrier method (use of condom [male partner] or diaphragm with spermicide or cervical cap with spermicide) from screening, or iii. Surgical sterilization of the partner (vasectomy ≥ 1 month before screening) AND a barrier method (use of condom [male partner] or diaphragm with spermicide or cervical cap with spermicide) from screening, or iv. Double-barrier methods (use of condom [male partner] with either diaphragm with spermicide or cervical cap with spermicide) from screening.

   b. For male patients i. Surgical sterilization (vasectomy ≥ 1 month before screening) AND a barrier method (use of condom or diaphragm with spermicide or cervical cap with spermicide) from screening, or ii. Consistently and correctly use a condom from screening AND female partner must agree to use a hormonal contraceptive, a nonhormonal nonbarrier method (eg, copper IUD), or a nonhormonal barrier method (eg, diaphragm with spermicide or cervical cap with spermicide).

Exclusion Criteria

1. Requirement for hospital admission
2. Current immunosuppression due to medication (steroids, biologics, chemotherapy) or underlying condition such as organ/bone marrow transplant or untreated HIV or HIV infection with detectable HIV RNA and/or CD4 count of <500.
3. Pregnancy (or positive urine pregnancy test) or lactating

4. The following pre-existing medical conditions:

   1. Known seizure disorder
   2. Known retinal disease requiring therapy
   3. Known autoimmune condition requiring therapy more intensive than intermittent non-steroidal anti-inflammatories in the prior 6 months (rheumatoid arthritis, lupus, inflammatory bowel disease)
   4. Known history of chronic obstructive pulmonary disease (COPD) or asthma associated with functional impairment
   5. Known cirrhosis with any history of decompensation (ascites, variceal bleeding or hepatic encephalopathy)
   6. Known chronic kidney disease with estimated creatinine clearance < 50 mL/minute or need for dialysis
   7. Severe psychiatric disorder - schizophrenia, bipolar disorder, depression with prior suicidality
   8. Any other underlying medical (cardiac, liver, renal, neurological, respiratory) or psychiatric condition that in the view of the investigator would preclude use of peginterferon lambda
5. Advanced cancer or other illness with life expectancy of < 1 year
6. Known alcohol or drug dependence that in the opinion of the investigator would impair study participation
7. Known prior intolerance to interferon treatment
8. Enrolment in another clinical trial with use of any investigational agent in the prior 30 days
9. Use of off-label therapy for COVID-19

Cohort B - Hospitalized

Inclusion Criteria

1. Adult patients over age 18
2. SARS-CoV-2 RNA-positive on nasopharyngeal swab/respiratory specimen within 10 days of symptom onset
3. Admitted to hospital for management of COVID-19
4. Willing and able to provide informed consent

5. Female patients of childbearing potential and male patients with partners of childbearing potential must agree to use adequate methods of contraception during the study and through 90 days after the last dose of study medication. Female patients of childbearing potential are all those except patients who are surgically sterile, who have medically documented ovarian failure, or who are at least 1 year postmenopausal. Adequate methods of contraception are:

   a. For female patients: i. Hormonal contraceptives including progestogen injection (eg, Depo-Provera®), combined oral contraceptive pill or vaginal ring for ≥ 3 months before screening AND a barrier method (use of condom [male partner] or diaphragm with spermicide or cervical cap with spermicide) from screening, or ii. Intrauterine device (IUD) or intrauterine system (IUS) in place ≥ 3 months before screening AND a barrier method (use of condom [male partner] or diaphragm with spermicide or cervical cap with spermicide) from screening, or iii. Surgical sterilization of the partner (vasectomy ≥ 1 month before screening) AND a barrier method (use of condom [male partner] or diaphragm with spermicide or cervical cap with spermicide) from screening, or iv. Double-barrier methods (use of condom [male partner] with either diaphragm with spermicide or cervical cap with spermicide) from screening.

   b. For male patients: i. Surgical sterilization (vasectomy ≥ 1 month before screening) AND a barrier method (use of condom or diaphragm with spermicide or cervical cap with spermicide) from screening, or ii. Consistently and correctly use a condom from screening AND female partner must agree to use a hormonal contraceptive, a nonhormonal nonbarrier method (eg, copper IUD), or a nonhormonal barrier method (eg, diaphragm with spermicide or cervical cap with spermicide).

Exclusion Criteria

1. Severity of illness

   1. Respiratory failure (requiring>6L O2 or intubation in the ER)
   2. Shock - systolic BP<90 mmHg or mean arterial BP<60 mmHg after fluid resuscitation
2. Current immunosuppression due to medication (steroids, biologics, chemotherapy) or underlying condition such as organ/bone marrow transplant or untreated HIV or HIV infection with detectable HIV RNA and/or CD4 count of <500.
3. Pregnancy (or positive urine pregnancy test) or lactating

4. The following pre-existing medical conditions:

   1. Known seizure disorder
   2. Known retinal disease requiring therapy
   3. Known autoimmune condition requiring therapy more intensive than intermittent non-steroidal anti-inflammatories in the prior 6 months (rheumatoid arthritis, lupus, inflammatory bowel disease)
   4. Known cirrhosis with any history of decompensation (ascites, variceal bleeding or hepatic encephalopathy)
   5. Known chronic kidney disease with estimated creatinine clearance < 30 mL/minute or need for dialysis
   6. Severe psychiatric disorder - uncontrolled schizophrenia, bipolar disorder, depression with prior suicidality
   7. Any other underlying medical (cardiac, liver, renal, neurological, respiratory) or psychiatric condition that in the view of the investigator would preclude use of peginterferon lambda
5. Known prior intolerance to interferon treatment
6. Enrolment in another clinical trial with use of an antiviral agent in the prior 30 days (co-enrollment with immunomodulatory agents permitted)
7. Use of off-label therapy for COVID-19

8. Any of the following abnormal laboratory indices

   1. Hemoglobin < 100 mg/dL
   2. Platelet count < 75,000 cells/mm3
   3. Absolute neutrophil count < 1,000 cells/mm3
   4. Estimated creatinine clearance < 30 cc/mL
   5. Total bilirubin > 2x upper limit of normal (ULN)
   6. Alanine aminotransferase (ALT) > 5x ULN
   7. Aspartate aminotransferase (AST) > 5x ULN
   8. Lipase or amylase > 2x ULN
   9. Random blood glucose > 20 mmol/L

Contacts and Locations

Contacts

Contact: Shinthuka Jeganathan, MBBS; (416) 340-4800 ext 6465; shinthuka.jeganathan@uhn.ca

Contact: Bethany Barber; (416) 340-4800 ext 6569; Bethany.Barber@uhn.ca

Locations

Brazil

Hospital das Clínicas da Faculdade de Medicina de Botucatu; Not yet recruiting

Botucatu, Brazil

Contact: Nelmara Camargo nelmara.camargo@unesp.br

Principal Investigator: Gabriel Almeida, MD

Hospital das Clínicas São Paulo; Recruiting

Sao Paulo, Brazil

Contact: Danielli Fragoso dbfragoso@uol.com.br

Principal Investigator: Evaldo Stanislau, MD

Hospital Alemão Oswaldo Cruz; Not yet recruiting

São Paulo, Brazil

Contact: Ana Caroline da Silva Lopes Moura anmoura@haoc.com.br

Principal Investigator: Icaro Boszczowski, MD

Canada, Alberta

University of Calgary; Recruiting

Calgary, Alberta, Canada, T2N 2T9

Contact: Traci Robinson traci.robinson@albertahealthservices.ca

Principal Investigator: Mark Gillrie, MD

Canada, Ontario

Michael Garron Hospital; Recruiting

Toronto, Ontario, Canada, M4C 3E7

Contact: Chris Kandel, MD 416-340-3505 christopher.kandel@one-mail.on.ca

Principal Investigator: Christopher Kandel, MD

Sunnybrook Health Sciences Centre; Recruiting

Toronto, Ontario, Canada, M4N 3M5

Contact: Nicole Marinoff nicole.marinoff@sunnybrook.ca

Principal Investigator: Neill Adhikari, MD

University Health Network; Recruiting

Toronto, Ontario, Canada, M5G 2C4

Contact: Shinthuka Jeganathan, MBBS 416-340-4800 ext 6465 shinthuka.jeganathan@uhn.ca

Contact: Bethany Barber 416-340-4800 ext 6569 Bethany.Barber@uhn.ca

Principal Investigator: Jordan J Feld, MD

Sponsors and Collaborators

University Health Network, Toronto

Michael Garron Hospital

Investigators

• Principal Investigator: Jordan Feld, MD; University Health Network, Toronto

  Study Documents (Full-Text)

Documents provided by University Health Network, Toronto:

Study Protocol  [PDF] January 24, 2021

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Feld JJ, Kandel C, Biondi MJ, Kozak RA, Zahoor MA, Lemieux C, Borgia SM, Boggild AK, Powis J, McCready J, Tan DHS, Chan T, Coburn B, Kumar D, Humar A, Chan A, O'Neil B, Noureldin S, Booth J, Hong R, Smookler D, Aleyadeh W, Patel A, Barber B, Casey J, Hiebert R, Mistry H, Choong I, Hislop C, Santer DM, Lorne Tyrrell D, Glenn JS, Gehring AJ, Janssen HLA, Hansen BE. Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial. Lancet Respir Med. 2021 May;9(5):498-510. doi: 10.1016/S2213-2600(20)30566-X. Epub 2021 Feb 5.

Lee JS, Shin EC. The type I interferon response in COVID-19: implications for treatment. Nat Rev Immunol. 2020 Oct;20(10):585-586. doi: 10.1038/s41577-020-00429-3.

Moschen AR. IBD in the time of corona - vigilance for immune-mediated diseases. Nat Rev Gastroenterol Hepatol. 2020 Sep;17(9):529-530. doi: 10.1038/s41575-020-0333-5.

• Responsible Party: University Health Network, Toronto
• ClinicalTrials.gov Identifier: NCT04354259
• Other Study ID Numbers: 20-5334
• First Posted: April 21, 2020
• Last Update Posted: January 19, 2022
• Last Verified: July 2021

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No
• Product Manufactured in and Exported from the U.S.: Yes

Keywords provided by University Health Network, Toronto:

peginterferon lambda

Additional relevant MeSH terms:

COVID-19; Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases